Related Experiment Video
Updated: Nov 14, 2025
04:49
Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research
Published on: May 5, 2021
6.7K
Patient-Derived Organoids for Precision Cancer Immunotherapy
Mikaela Grönholm1,2,3,4, Michaela Feodoroff1,2,4,5, Gabriella Antignani1,2,4
1Laboratory of ImmunoViroTherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Cancer Research
|March 10, 2021
Summary
Developing new cancer immunotherapy testing platforms is crucial. Patient-derived tumor organoids and immune-organoid cultures offer promising preclinical models for personalized cancer treatment selection.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Cancer immunotherapy has transformed tumor treatment.
- Clinically relevant human ex vivo tumor assays for pretreatment testing are needed.
- Current platforms lack the necessary complexity, including the tumor microenvironment and immune cells.
Purpose of the Study:
- To discuss the applications of patient-derived tumor organoid cultures.
- To explore the potential of complex immune-organoid cultures.
- To establish preclinical testing platforms for precision cancer immunotherapy.
Main Methods:
- Utilizing patient-derived tumor organoid cultures.
- Developing complex co-culture systems with immune cells.
- Evaluating these models as preclinical testing platforms.
Main Results:
- Patient-derived tumor organoids can model human tumors.
- Immune-organoid cultures incorporate key elements of the tumor microenvironment.
- These complex cultures show potential for preclinical immunotherapy testing.
Conclusions:
- Patient-derived tumor organoids are valuable tools in cancer research.
- Complex immune-organoid cultures represent a significant advancement for preclinical testing.
- These platforms can facilitate the selection of effective and safe precision cancer immunotherapies.
